A. TNF-inhibitor naïve patients had better response B. Patients did not respond after TNF-inhibitor failure C. Maintenance response was evaluated after 20 weeks D. Dosing every 12 weeks showed improved response versus every 8 weeks

A. IL 12/23 inhibitor B. TNF-inhibitor C. Anti-adhesion molecule D. IL-23 inhibitor targeting the p19 subunit

A. Ustekinumab and rizankizumab B. Darvadstrocel and filgotinib C. Filgotinib and ozanimod D. Etrasimod and darvadstrocel

A. Herpes zoster rates are higher in IBD patients, regardless of treatment B. Herpes zoster rates for UC patients on thiopurines are similar to patients without IBD C. Pneumonia risk is higher only for patients with Crohn's disease D. Pneumonia incidence is only increased in UC patients with corticosteroid use

A. Infliximab B. Adalimumab C. Vedolizumab D. Certolizumab pegol

A. PCV13 and PPSV23 are contraindicated in patients with IBD B. PCV13 and PPSV23 are contraindicated with biologics or other immunosuppressants C. Patient misconceptions/lack of education D. Treatment from both primary care and gastroenterology

A. Indicated for patients older than 60 years B. A subcutaneous, two-dose series that is administered at least 6 months apart C. Not necessary in patients who have previously received the live zoster vaccine D. A two-dose series that may cause myalgia and fatigue

A. Pap smear, skin cancer screening, colonoscopy B. Bone mineral density (with risk factors), skin cancer screening, depression screening C. Skin cancer screening, EKG, smoking cessation counseling D. Vitamin D levels, EKG, colonoscopy

A. MMR B. Recombinant zoster vaccine C. Hepatitis A D. Meningococcal

A. A patient with protein calorie malnutrition B. A patient on infliximab C. A patient on ustekinumab D. A 68 kg male on 100 mg of 6-mercaptopurine daily